SCYNEXIS (SCYX) Competitors $0.88 +0.14 (+19.54%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.89 +0.02 (+1.94%) As of 08/7/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCYX vs. ATOS, SKYE, HURA, ZURA, SAVA, HLVX, COYA, CHRS, MGNX, and CLYMShould you be buying SCYNEXIS stock or one of its competitors? The main competitors of SCYNEXIS include Atossa Genetics (ATOS), Skye Bioscience (SKYE), TuHURA Biosciences (HURA), Zura Bio (ZURA), Cassava Sciences (SAVA), HilleVax (HLVX), Coya Therapeutics (COYA), Coherus Oncology (CHRS), MacroGenics (MGNX), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry. SCYNEXIS vs. Its Competitors Atossa Genetics Skye Bioscience TuHURA Biosciences Zura Bio Cassava Sciences HilleVax Coya Therapeutics Coherus Oncology MacroGenics Climb Bio Atossa Genetics (NASDAQ:ATOS) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation. Does the media favor ATOS or SCYX? In the previous week, Atossa Genetics had 3 more articles in the media than SCYNEXIS. MarketBeat recorded 3 mentions for Atossa Genetics and 0 mentions for SCYNEXIS. Atossa Genetics' average media sentiment score of 0.20 beat SCYNEXIS's score of 0.00 indicating that Atossa Genetics is being referred to more favorably in the media. Company Overall Sentiment Atossa Genetics Neutral SCYNEXIS Neutral Which has more volatility and risk, ATOS or SCYX? Atossa Genetics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Do insiders & institutionals believe in ATOS or SCYX? 12.7% of Atossa Genetics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 7.6% of Atossa Genetics shares are owned by insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend ATOS or SCYX? Atossa Genetics presently has a consensus price target of $6.17, indicating a potential upside of 700.87%. Given Atossa Genetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Atossa Genetics is more favorable than SCYNEXIS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Genetics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33SCYNEXIS 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, ATOS or SCYX? SCYNEXIS has higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa GeneticsN/AN/A-$25.50M-$0.21-3.67SCYNEXIS$3.75M9.10-$21.29M-$0.56-1.56 Is ATOS or SCYX more profitable? Atossa Genetics has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. Atossa Genetics' return on equity of -33.90% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets Atossa GeneticsN/A -33.90% -31.53% SCYNEXIS -1,030.04%-53.47%-32.86% SummaryAtossa Genetics beats SCYNEXIS on 11 of the 16 factors compared between the two stocks. Get SCYNEXIS News Delivered to You Automatically Sign up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCYX vs. The Competition Export to ExcelMetricSCYNEXISMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.56M$2.51B$5.48B$9.57BDividend YieldN/A1.78%3.99%4.17%P/E Ratio-1.5619.6629.8525.14Price / Sales9.10634.78422.3397.16Price / CashN/A165.0335.9458.58Price / Book0.604.198.125.59Net Income-$21.29M$31.61M$3.26B$265.48M7 Day Performance28.47%0.95%0.68%1.22%1 Month Performance23.17%2.90%2.46%0.39%1 Year Performance-54.19%4.11%27.99%23.47% SCYNEXIS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCYXSCYNEXIS0.5584 of 5 stars$0.88+19.5%N/A-53.0%$28.56M$3.75M-1.5660Upcoming EarningsGap UpHigh Trading VolumeATOSAtossa Genetics2.5974 of 5 stars$0.83+1.3%$6.17+639.7%-33.6%$106.31MN/A-3.978Upcoming EarningsSKYESkye Bioscience1.4604 of 5 stars$3.63+6.5%$16.60+357.3%-31.2%$105.63MN/A-4.4311News CoverageEarnings ReportHURATuHURA Biosciences1.2863 of 5 stars$2.59+7.9%$12.67+389.1%N/A$104.83MN/A0.00N/AZURAZura Bio3.7404 of 5 stars$1.46-2.7%$14.33+881.7%-58.1%$102.56MN/A-2.093Upcoming EarningsSAVACassava Sciences3.8469 of 5 stars$2.29+8.0%$54.50+2,279.9%-92.7%$102.41MN/A-1.5330News CoverageUpcoming EarningsHLVXHilleVax1.9215 of 5 stars$2.07+1.5%$2.00-3.4%+28.0%$102.29MN/A-0.9620News CoverageEarnings ReportUpcoming EarningsHigh Trading VolumeCOYACoya Therapeutics2.1533 of 5 stars$6.34+4.1%$16.50+160.3%+2.3%$101.86M$3.55M-5.936Upcoming EarningsCHRSCoherus Oncology3.9267 of 5 stars$0.87-1.1%$4.68+439.6%-28.7%$101.77M$266.96M-0.77330News CoverageEarnings ReportMGNXMacroGenics4.2626 of 5 stars$1.64+3.8%$5.33+225.2%-52.4%$99.68M$149.96M-1.84430CLYMClimb Bio2.7151 of 5 stars$1.70+17.2%$9.00+429.4%N/A$97.99MN/A-0.719News CoverageUpcoming EarningsGap UpHigh Trading Volume Related Companies and Tools Related Companies ATOS Alternatives SKYE Alternatives HURA Alternatives ZURA Alternatives SAVA Alternatives HLVX Alternatives COYA Alternatives CHRS Alternatives MGNX Alternatives CLYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCYX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SCYNEXIS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
